Pharmaceuticals News and Research

RSS

Eli Lilly, Alnara sign definitive merger agreement

Eli Lilly and Company and Alnara Pharmaceuticals, Inc. today announced they have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases. Alnara's lead product in development is liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT).

2 Jul 2010

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.

2 Jul 2010

Columbia Laboratories shareholders approve Watson's aquisition terms

Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that shareholders of Columbia Laboratories, Inc. (Nasdaq: CBRX) have approved the terms and conditions of the previously announced acquisition by Watson of the U.S. rights to Columbia's CRINONE® and PROCHIEVE® progesterone gel product line and 11,200,000 shares of Columbia common stock.

2 Jul 2010

Investment report on Arena Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Arena Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

2 Jul 2010

Visually impaired people dose accurately with insulin pens: Study

Labels on the popular insulin pen used by people with diabetes warn against visually-impaired people using pens to measure out and administer their insulin dosage.

2 Jul 2010

Institute of Food Research unveils new emulsifier technique

New work from the Institute of Food Research has shown how sugar beet pectin acts as an efficient emulsifier, using a technique that could be used to unravel in the finest detail how such important food ingredients work.

2 Jul 2010

ClinTec International CRO expands US based operations with launch of New York office

UK-based Global Clinical Research Organisation (CRO), ClinTec International has unveiled a significant expansion into the US marketplace, with the launch of its New York office and the appointment of Susan Pavone, Associate Director of US Business Operations.

2 Jul 2010

Columbia Laboratories' sale of progesterone related assets to Watson receives stockholder approval

Columbia Laboratories, Inc. announced that in a special meeting of stockholders held this morning, stockholders approved the sale of substantially all of Columbia's progesterone related assets to Watson Pharmaceuticals, Inc.. Stockholders also voted to increase the number of authorized shares of Columbia's common stock, $0.01 par value per share, from 100,000,000 to 150,000,000.

2 Jul 2010

Anti-aging supplement: A fountain of hope for would-be mothers

According to the American Pregnancy Association, six million women a year deal with infertility. Now, a Tel Aviv University study is giving new hope to women who want to conceive ― in the form of a pill they can find on their drugstore shelves right now.

2 Jul 2010

Javelin announces successful completion of tender offer by Hospira subsidiary

Javelin Pharmaceuticals, Inc., today announced the successful completion of the tender offer by Discus Acquisition Corporation, a wholly owned subsidiary of Hospira, Inc., to purchase all outstanding shares of the common stock of Javelin.

2 Jul 2010

Teva launches antidepressant Venlafaxine HCl ER Capsules

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of Venlafaxine HCl ER Capsules, the Company's generic version of Wyeth's antidepressant Effexor XR®. The brand product had annual sales of approximately $2.75 billion in the United States, based on IMS sales data.

2 Jul 2010

China PharmaHub announces new joint venture for humanized antibody

China PharmaHub Corp., announced today that it has entered into a definitive agreement with Dr. David Weaver and Dr. Michael Rynkiewicz. In addition, PharmaHub contemplates merging with World Wide Relics, Inc. of which it recently purchased a 77% interest.

2 Jul 2010

Caraco Pharmaceutical Laboratories commences marketing of rivastigmine tartrate capsules

Caraco Pharmaceutical Laboratories, Ltd. has started shipping rivastigmine tartrate capsules. These products, approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA), are therapeutically equivalent to Exelon® capsules from Novartis.

2 Jul 2010

GSK, Genmab amend ofatumumab agreement

GlaxoSmithKline and Genmab A/S announced today an amendment to the ofatumumab co-development and commercialisation agreement. Under the terms of the amendment, GSK will take responsibility for developing ofatumumab in autoimmune indications whilst continuing to jointly develop ofatumumab with Genmab in oncology indications.

2 Jul 2010

USPTO awards Furiex method patent for dapoxetine in treatment of premature ejaculation

Furiex Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office issued a patent on May 18, 2010, for the method for treatment of premature ejaculation using dapoxetine. Furiex developed dapoxetine in collaboration with Alza Corporation and its affiliates. U.S. Patent No. 7,718,705 includes claims directed to dosing dapoxetine on an as-needed basis, capturing the advantage dapoxetine has over other compounds in the same class, which require a pre-loading period for efficacy.

2 Jul 2010

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

United Therapeutics Corporation and Lee's Pharmaceutical Holdings Ltd. announced today that they have entered into an exclusive agreement for the distribution of Remodulin (treprostinil) Injection in China. Remodulin is a subcutaneously or intravenously administered prostacyclin analogue for the treatment of pulmonary arterial hypertension. Lee's Pharmaceutical is a leading Chinese pharmaceutical company with both a strong cardiovascular focus and extensive commercialization experience.

2 Jul 2010

DARA BioSciences suspends $10M underwritten public offering

On May 17, 2010, DARA BioSciences, Inc. issued a press release announcing that it had commenced an underwritten public offering of $10 million of units comprised of shares of common stock and warrants. DARA has decided to indefinitely suspend the offering, effective immediately. Several important factors have influenced this decision.

2 Jul 2010

Advanced Analytical opens new sales office, lab in Technologiepark at Heidelberg University

Advanced Analytical, headquartered in Ames, IA, has opened a new sales office and laboratory in Heidelberg Germany. The new facility is located in the Technologiepark on the campus of the Heidelberg University. By opening this office, the company will be able to provide better representation over sales for our suite of products sold as well as provide better support and service for our current and future customer base.

2 Jul 2010

Lupin's Famotidine for Oral Suspension receives FDA approval

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the US Food and Drug Administration (FDA) for its Famotidine for Oral Suspension (40 mg / 5 mL). Commercial shipments of the product have already commenced.

2 Jul 2010

Hospira subsidiary completes tender offer for Javelin's outstanding shares of common stock

Hospira, Inc., a global specialty pharmaceutical and medication delivery company, today announced the successful completion of the tender offer by Discus Acquisition Corporation, a wholly owned Hospira subsidiary, to purchase all outstanding shares of the common stock of Javelin Pharmaceuticals, Inc..

1 Jul 2010

Pharmaceuticals News and Research

Eli Lilly, Alnara sign definitive merger agreement

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Columbia Laboratories shareholders approve Watson's aquisition terms

Investment report on Arena Pharmaceuticals

Visually impaired people dose accurately with insulin pens: Study

Institute of Food Research unveils new emulsifier technique

ClinTec International CRO expands US based operations with launch of New York office

Columbia Laboratories' sale of progesterone related assets to Watson receives stockholder approval

Anti-aging supplement: A fountain of hope for would-be mothers

Javelin announces successful completion of tender offer by Hospira subsidiary

Teva launches antidepressant Venlafaxine HCl ER Capsules

China PharmaHub announces new joint venture for humanized antibody

Caraco Pharmaceutical Laboratories commences marketing of rivastigmine tartrate capsules

GSK, Genmab amend ofatumumab agreement

USPTO awards Furiex method patent for dapoxetine in treatment of premature ejaculation

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

DARA BioSciences suspends $10M underwritten public offering

Advanced Analytical opens new sales office, lab in Technologiepark at Heidelberg University

Lupin's Famotidine for Oral Suspension receives FDA approval

Hospira subsidiary completes tender offer for Javelin's outstanding shares of common stock

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence